| 名稱(chēng) | ADCP Bioassay Effector Cell FcγRIIa （H variant）-NF |
| 型號(hào) | CBP74106 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | ADCP Bioassay Effector Cell FcγRIIa （H variant）-NFAT/Jurkat，母細(xì)胞：Jurkat，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- 人結(jié)腸癌細(xì)胞株的生長(zhǎng)曲線分析
- 腫瘤細(xì)胞的凋亡與壞死有何區(qū)別？
- 【產(chǎn)品推介】RANKL抗體篩選模型
- 4-1BB（CD137）靶點(diǎn)藥物篩選模型
- KRAS G12C耐藥突變藥篩細(xì)胞模型
- CD47/PD-(L)1 雙靶點(diǎn)細(xì)胞篩選模型簡(jiǎn)介
- 慢病毒整合位點(diǎn)標(biāo)準(zhǔn)品強(qiáng)勢(shì)來(lái)襲
- PTPRZ1-MET腦膠質(zhì)瘤分子診斷標(biāo)準(zhǔn)品上新
- EGFR 20外顯子突變類(lèi)型標(biāo)準(zhǔn)品
- 探討腫瘤細(xì)胞的“冷與熱”之分
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74106ADCP Bioassay Effector Cell FcγRIIa （H variant）-NF
- 詳細(xì)內(nèi)容
| CBP74106 | |
| I. Background | |
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. FcγRIIa is the predominant Fcγ receptor involved in the ADCP process. FcγRIIa is expressed in myeloid effector cells, including macrophages and neutrophils, where it plays a role in the activation of these effector cells. Several clinical studies have studied the correlation of a FcγRIIa polymorphism (R131H) and the response to IgG1 subclass monoclonal antibodies (mAbs) such as rituximab. Engineered amino-acid substitutions in Fc-mAbs have been developed to enhance the mAb-mediated phagocytosis of tumor cells by macrophages. | |
| II. Description | |
Recombinant Jurkat T cell expressing a firefly luciferase gene under the control of NFAT response elements with constitutive expression of human FcγRIIa, Histidine variant. | |
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | FcγRIIa (H variant)-NFAT |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+400ug/ml hygromycin |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
| |
Figure 1：Dose response of Rituximab in ADCP Bioassay Effector Cell FcyRlla (H variant) /NFAT Reporter-Jurkat (C2)，the EC50 was 21.5ng/ml. | |
會(huì)員_a.png)